Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00035412 · ClinicalTrials.gov registry record · Phase 2

St. John's Wort Versus Placebo in Social Phobia

A Phase 2 study of Phobic Disorders, sponsored by National Center for Complementary and Integrative Health (NCCIH).

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT00035412: Completed Phase 2 study of Phobic Disorders, sponsored by National Center for Complementary and Integrative Health (NCCIH).

NCT00035412 is a Phase 2 study of Phobic Disorders that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 40 participants, below the 113-participant average among 5 other Phobic Disorders trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00035412, a Phase 2 study of Phobic Disorders, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effectiveness of St. John's Wort as compared to placebo (an inactive substance) in the treatment of outpatients with social phobia.

Conditions Studied

Interventions

  • DRUG St. John's Wort

Study Locations (1)

Wisconsin

  • The Dean Foundation for Health, Research, and Education - Madison

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2001-12
Est. Completion 2004-08
Phase Phase 2

What the finished NCT00035412 record still lists

NCT00035412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 113-participant average among 5 other Phobic Disorders trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Phobic Disorders appearing as the primary indexed condition, and to 1 intervention - of which St. John's Wort is the first listed.

NCT00035412 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00035412 about?

NCT00035412 is a clinical study titled "St. John's Wort Versus Placebo in Social Phobia". The purpose of this study is to determine the effectiveness of St. John's Wort as compared to placebo (an inactive substance) in the treatment of outpatients with social phobia.

What is the current status of trial NCT00035412?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-12. Estimated completion is 2004-08.

What conditions does trial NCT00035412 study?

This clinical trial studies the following conditions: Phobic Disorders.

What interventions are being tested in trial NCT00035412?

The interventions under investigation include: St. John's Wort (DRUG).

Who is sponsoring clinical trial NCT00035412?

This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00035412 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Phobic Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00035412, the US trial registry maintained by the National Library of Medicine. NCT00035412 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.